Samil Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Samil Pharmaceutical makes medicines for everyday use, including a children's ibuprofen syrup and eye-care and digestive products, as well as prescription drugs focused on ophthalmology, liver disease, and gastrointestinal conditions.
Its products reach patients through hospitals, clinics, and pharmacies across South Korea. Listed on KOSPI, Korea's main stock exchange, the company earns revenue both from drugs it develops and manufactures itself, including generics and improved reformulations, and from original branded medicines it imports and distributes exclusively in Korea.
Summary is AI-generated and may contain errors · figures from DART filings
The company operates a contract manufacturing facility in Vietnam built to international pharmaceutical quality standards, focused on ophthalmic products for global customers.
Samil Pharmaceutical in five facts
What does Samil Pharmaceutical do?
Samil Pharmaceutical makes medicines for everyday use, including a children's ibuprofen syrup and eye-care and digestive products, as well as prescription drugs focused on ophthalmology, liver disease, and gastrointestinal conditions.
Where is Samil Pharmaceutical listed and in which sector?
Samil Pharmaceutical (Korean name: 삼일제약) trades under KRX code 000520 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Samil Pharmaceutical?
Its market capitalisation was US$134.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Samil Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Samil Pharmaceutical reported revenue of US$158.7M, an operating loss of US$16.8M and a net loss of US$26.2M, per its annual report on DART (data retrieved from DART on 2026-09-05). Revenue was down 4.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-05
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 19
- Report on large shareholdings (5% rule) (standard)Oct 12
- Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Jun 19
- Material event report (convertible bonds)
Samil Pharmaceutical disclosed convertible bonds to raise US$6.59M, about 5.3% of its market value.
Capital raise · Jun 11 - Treasury share disposal: results reportTreasury Shares · Feb 27
- Material event report (treasury share disposal)
Samil Pharmaceutical disclosed a plan to sell treasury shares worth US$1.15M, about 0.9% of its market value.
Treasury Shares · Feb 26 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 26
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 26